Montol (Montelukast)

• Montol (montelukast) acts on the leukotriene pathway to control airway and nasal inflammation.
• Asthma: Improves control of chronic asthma and reduces frequency of exacerbations.
• Allergic rhinitis: Relieves nasal congestion, sneezing and itching associated with seasonal allergies.
• Exercise‑induced bronchoconstriction: Prevents narrowing of the airways triggered by physical activity.

• Montelukast selectively blocks the cysteinyl leukotriene receptor type 1 (CysLT1) on airway smooth‑muscle cells, mast cells and eosinophils. By antagonizing this receptor, it prevents leukotriene‑mediated bronchoconstriction, mucus secretion, vascular permeability and inflammatory cell recruitment, thereby reducing airway hyper‑responsiveness and nasal mucosal edema. The inhibition is competitive and reversible, allowing normal leukotriene synthesis while limiting their pathological actions, and contributes to improved pulmonary function and symptom control.

Montelukast is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects

• Headache: mild to moderate headache that may be intermittent.
• Abdominal pain: discomfort or cramps in the stomach area, sometimes with bloating.
• Cough: occasional dry cough without mucus production.
• Nausea: feeling of queasiness that may lead to vomiting.

Serious or Rare Side Effects

• Stevens‑Johnson syndrome: severe skin reaction characterized by blistering and detachment of epidermis.
• Angioedema: rapid swelling of the face, lips, tongue or throat that can impair breathing.
• Neuropsychiatric events: mood changes such as depression, anxiety, or suicidal thoughts, requiring immediate medical attention.

• Before prescribing Montol, clinicians should consider several precautionary measures to ensure safe use.
• Assess asthma control: confirm that the patient’s asthma is not uncontrolled before initiating therapy.
• Monitor neuropsychiatric symptoms: watch for mood changes, depression, or suicidal thoughts during treatment.
• Use with caution in hepatic impairment: dose adjustment may be needed for patients with liver dysfunction.
• Avoid in known hypersensitivity: discontinue if allergic reaction to montelukast or any excipients occurs.
• Pregnancy and lactation: prescribe only if the potential benefit justifies the potential risk to the fetus or infant.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, affecting its plasma concentration or therapeutic effect.

Major Interactions (Avoid)

• Rifampin: strong enzyme inducer that can markedly reduce montelukast levels, decreasing efficacy.
• Ketoconazole: potent CYP3A4 inhibitor that can increase montelukast exposure, raising risk of adverse effects.

Moderate Interactions (Monitor Closely)

• Phenobarbital: moderate enzyme inducer that may lower montelukast concentrations.
• Warfarin: possible alteration of anticoagulant effect; monitor INR when starting or stopping montelukast.
• Carbamazepine: enzyme inducer that can modestly decrease montelukast plasma levels.